Join the Faslodex group to help and get support from people like you.
Faslodex News
Neratinib, Fulvestrant, Trastuzumab Combo Aids Metastatic Breast Cancer
TUESDAY, Nov. 28, 2023 – For patients with hormone receptor (HR)-positive HER2-mutant metastatic breast cancer (MBC) with progression on cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) therapy,...
Faslodex (fulvestrant) Receives FDA Approval as Monotherapy for Expanded Use in HR+, HER2- Advanced Breast Cancer
August 28, 2017 – AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved Faslodex (fulvestrant) 500mg as monotherapy for expanded use in women with hormone-receptor...
FDA Approves New Dosing for Faslodex (fulvestrant) Injection in Treatment of Metastatic Breast Cancer in HR+ Postmenopausal Women
WILMINGTON, Del., Sept. 10 /PRNewswire-FirstCall/ – AstraZeneca today announced that the U.S. Food and Drug Administration (FDA) has approved the 500mg dose of Faslodex (fulvestrant) Injection,...
Further information
Related condition support groups
Breast Cancer, Metastatic, Breast Cancer